Phenethylamine compounds salts, polymorphic forms and methods of use thereof
AssigneeTerran Biosciences Inc.
InventorSamuel Clark
Life of this patent
Estimating the term…
Abstract
Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and/or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and/or a psychiatric disorder in a subject.
Claims38
A solid form of (R)-3,4-methylenedioxy-methamphetamine ((R)-MDMA) HCl salt, wherein the solid form is characterized by an XRPD spectrum comprising two or three XRPD signals at 7.9° 2θ, 14.0° 2θ, and 15.7° 2θ (±0.2° 2θ;
- ±0.1° 2θ;
- or ±0.0° 2θ;
- Cu Kα1 radiation).
A solid form of (R)-3,4-methylenedioxy-methamphetamine ((R)-MDMA) HCl salt wherein the solid form of (R)-MDMA HCl is characterized by an XRPD spectrum comprising two or more XRPD signals in Table 67B (±0.2° 2θ;
- ±0.1° 2θ;
- or ±0.0° 2θ;
- Cu Kα1 radiation).
A solid form of (R)-3,4-methylenedioxy-methamphetamine ((R)-MDMA) HCl salt wherein the solid form of (R)-MDMA HCl is characterized by an XRPD spectrum substantially similar to that shown in FIG. 15 or FIG. 16.
A solid form of (R)-MDMA HCl salt, wherein the solid form is characterized an XRPD spectrum comprising two or three XRPD signals at 15.7° 2θ, 17.4° 2θ, and 20.6° 2θ (±0.2° 2θ;
- ±0.1° 2θ;
- or ±0.0° 2θ;
- Cu Kα1 radiation).
A solid form of(S)-3,4-methylenedioxy-methamphetamine ((S)-MDMA) HCl salt, wherein the solid form is characterized by an XRPD spectrum comprising two or three XRPD signals at 7.9° 2θ, 14.0° 2θ, and 15.7° 2θ (±0.2° 2θ;
- ±0.1° 2θ;
- or ±0.0° 2θ;
- Cu Kα1 radiation).
A solid form of(S)-3,4-methylenedioxy-methamphetamine ((S)-MDMA) HCl salt, wherein the solid form of(S)-MDMA HCl is characterized by an XRPD spectrum comprising two or more XRPD signals in Table 67A (±0.2° 2θ;
- ±0.1° 2θ;
- or ±0.0° 2θ;
- Cu Kα1 radiation).
A solid form of(S)-3,4-methylenedioxy-methamphetamine ((S)-MDMA) HCl salt, wherein the solid form of(S)-MDMA HCl is further characterized by a XRPD spectrum substantially similar to that shown in FIG. 13 or FIG. 14.
A solid form of(S)-MDMA HCl salt, wherein the solid form is characterized by an XRPD spectrum comprising two or three XRPD signals at 15.7° 2θ, 17.4° 2θ, and 20.6° 2θ (±0.2° 2θ;
- ±0.1° 2θ;
- or ±0.0° 2θ;
- Cu Kα1 radiation).
Dependencies are inferred from the claim text.